Accelerating Clinical Applications through New Technology Development and Joint Research
First written in FY2019. 16 of 17 entries say "Restated". Latest entry: FY2025-H1.
15 other companies' latest entry also says "Restated".
- FY2025-H1RestatedAnnual report
「Our research and development activities are conducted mainly in collaboration with universities and operating companies on the clinical application of regenerative medicine using autologous cells and tissues. R&D expenses for the interim consolidated accounting period amounted to ¥10,433 thousand.」
The policy of advancing clinical applications of autologous cells and tissues through joint research with universities and operating companies remains in place. R&D expenses were stated as ¥10,433 thousand. - FY2024-Q1RestatedAnnual report
「Our research and development activities are conducted mainly in collaboration with universities and operating companies on the clinical application of regenerative medicine using autologous cells and tissues. R&D expenses for the cumulative first quarter amounted to ¥15,459 thousand.」
The policy of advancing clinical applications of autologous cells and tissues through joint research with universities and operating companies remains in place. R&D expenses were stated as ¥15,459 thousand, but no progress to a new clinical stage was indicated. - FY2023-Q3RestatedAnnual report
「Our research and development activities are conducted mainly in collaboration with universities and operating companies on the clinical application of regenerative medicine using autologous cells and tissues. R&D expenses for the cumulative third quarter amounted to ¥58,928 thousand.」
The policy of advancing clinical applications of autologous cells and tissues through joint research with universities and operating companies remains in place. R&D expenses were stated as ¥58,928 thousand, but no progress to a new clinical stage was indicated. - FY2023-Q2RestatedAnnual report
「Our research and development activities are conducted mainly in collaboration with universities and operating companies on the clinical application of regenerative medicine using autologous cells and tissues. R&D expenses for the cumulative second quarter amounted to ¥43,056 thousand.」
The policy of advancing clinical applications of autologous cells and tissues in collaboration with universities and operating companies remains in place. R&D expenses for the cumulative second quarter were ¥43,056 thousand, and no progress to a new clinical stage was indicated. - FY2023-Q1RestatedAnnual report
「Our research and development activities are conducted mainly in collaboration with universities and operating companies on the clinical application of regenerative medicine using autologous cells and tissues. R&D expenses for the cumulative first quarter amounted to ¥26,864 thousand.」
The policy of advancing clinical applications of autologous cells and tissues through joint research with universities and operating companies remains in place. First-quarter R&D expenses were stated as ¥26,864 thousand, but no progress to a new clinical stage was indicated. - FY2022RestatedAnnual report
「Our research and development activities are conducted mainly in collaboration with universities and operating companies on the clinical application of regenerative medicine using autologous cells and tissues.」
The policy of advancing clinical applications through joint research with universities and operating companies remains in place. R&D expenses amounted to ¥87,562 thousand. - FY2022-Q3RestatedAnnual report
「Our research and development activities are conducted mainly in collaboration with universities and operating companies on the clinical application of regenerative medicine using autologous cells and tissues. R&D expenses for the cumulative third quarter amounted to ¥65,887 thousand.」
The policy of advancing clinical applications of autologous cells and tissues through joint research with universities and operating companies remains in place. R&D expenses amounted to ¥65,887 thousand, but no progress to a new clinical stage was indicated. - FY2022-Q2RestatedAnnual report
「Our research and development activities are conducted mainly in collaboration with universities and operating companies on the clinical application of regenerative medicine using autologous cells and tissues. R&D expenses for the cumulative second quarter amounted to ¥43,249 thousand.」
The policy of advancing clinical applications of autologous cells and tissues in collaboration with universities and operating companies remains in place. R&D expenses were stated as ¥43,249 thousand, but no progress to a new clinical stage was indicated. - FY2022-Q1RestatedAnnual report
「Our research and development activities are conducted mainly in collaboration with universities and operating companies on the clinical application of regenerative medicine using autologous cells and tissues. R&D expenses for the cumulative first quarter amounted to ¥17,188 thousand.」
The policy of advancing clinical applications of autologous cells and tissues in collaboration with universities and operating companies remains in place. R&D expenses were stated as ¥17,188 thousand, but no progress to a new clinical stage was indicated. - FY2021RestatedAnnual report
「Our research and development activities are conducted mainly in collaboration with universities and operating companies on the clinical application of regenerative medicine using autologous cells and tissues.」
The policy of advancing clinical applications of autologous cells and tissues through joint research with universities and operating companies remains in place. R&D expenses amounted to ¥71,161 thousand. - FY2021-Q2RestatedAnnual report
「Our research and development activities are conducted mainly in collaboration with universities and operating companies on the clinical application of regenerative medicine using autologous cells and tissues. R&D expenses for the cumulative second quarter amounted to ¥38,122 thousand.」
The policy of advancing clinical applications of autologous cells and tissues through joint research with universities and operating companies remains in place. R&D expenses were stated as ¥38,122 thousand, but no progress to a new clinical stage was indicated. - FY2021-Q1RestatedAnnual report
「Our research and development activities are conducted mainly in collaboration with universities and operating companies on the clinical application of regenerative medicine using autologous cells and tissues. R&D expenses for the cumulative first quarter amounted to ¥15,411 thousand.」
The policy of advancing clinical applications of autologous cells and tissues through joint research with universities and operating companies remains in place. R&D expenses were stated as ¥15,411 thousand, but no progress to a new clinical stage was indicated. - FY2020RestatedAnnual report
「Our research and development activities are conducted mainly in collaboration with universities and operating companies on the clinical application of regenerative medicine using autologous cells and tissues. R&D expenses for the fiscal year amounted to ¥10,817 thousand, all of which were R&D expenses in the regenerative medicine-related business.」
The policy of advancing clinical applications of autologous cells and tissues through joint research with universities and operating companies remains in place. R&D expenses were stated as ¥10,817 thousand, but no progress to a new clinical stage was indicated. - FY2020-Q3RestatedAnnual report
「Our research and development activities are conducted mainly in collaboration with universities and operating companies on the clinical application of regenerative medicine using autologous cells and tissues. R&D expenses for the cumulative third quarter amounted to ¥5,972 thousand, all of which were R&D expenses in the regenerative medicine-related business.」
The policy of advancing clinical applications using autologous cells and tissues in collaboration with universities and operating companies remains in place. R&D expenses for the cumulative third quarter were stated as ¥5,972 thousand, but no new stage of progress was indicated. - FY2020-Q2RestatedAnnual report
「Our research and development activities are conducted mainly in collaboration with universities and operating companies on the clinical application of regenerative medicine using autologous cells and tissues. R&D expenses for the cumulative second quarter amounted to ¥2,103 thousand, all of which were R&D expenses in the regenerative medicine-related business.」
The policy of advancing clinical applications using autologous cells and tissues in collaboration with universities and operating companies remains in place. R&D expenses for the cumulative second quarter were stated as ¥2,103 thousand. - FY2020-Q1RestatedAnnual report
「Our research and development activities are conducted mainly in collaboration with universities and operating companies on the clinical application of regenerative medicine using autologous cells and tissues. R&D expenses for the cumulative first quarter amounted to ¥499 thousand, all of which were R&D expenses in the regenerative medicine-related business.」
The policy of advancing the clinical application of autologous cells and tissues in collaboration with universities and operating companies remains in place. First-quarter R&D expenses were stated as ¥499 thousand. - FY2019First statedAnnual report
「Accelerating the development of clinical applications through active participation in new technology development and joint research related to regenerative medicine」
Participation in new technology development and joint research is being pursued as a means of advancing clinical applications.